Eyepoint Pharmaceuticals (NASDAQ:EYPT) vs. Celcuity (NASDAQ:CELC) Financial Comparison

Celcuity (NASDAQ:CELC) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Risk & Volatility

Celcuity has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500.

Institutional & Insider Ownership

63.3% of Celcuity shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 13.3% of Celcuity shares are owned by insiders. Comparatively, 4.5% of Eyepoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Celcuity and Eyepoint Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-244.61%	-50.22%
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

Analyst Ratings

This is a breakdown of current ratings for Celcuity and Eyepoint Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1	0	11	0	2.83
Eyepoint Pharmaceuticals	1	0	4	2	3.00

Celcuity currently has a consensus price target of $149.30, indicating a potential upside of 8.01%. Eyepoint Pharmaceuticals has a consensus price target of $31.80, indicating a potential upside of 145.94%. Given Eyepoint Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Celcuity.

Valuation and Earnings

This table compares Celcuity and Eyepoint Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04 million	($3.90)	-35.44
Eyepoint Pharmaceuticals	$7.61 million	142.38	-$231.96 million	($3.50)	-3.69

Celcuity has higher earnings, but lower revenue than Eyepoint Pharmaceuticals. Celcuity is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Eyepoint Pharmaceuticals beats Celcuity on 9 of the 14 factors compared between the two stocks.

About Celcuity

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.